Nordson MEDICAL Completes Divestiture of Select Contract Manufacturing Products, Narrowing its Focus on Proprietary Medical Components

WESTLAKE, Ohio--(BUSINESS WIRE)--Nordson Corporation (Nasdaq: NDSN) has completed the divestiture of select product lines within its medical contract manufacturing business to Quasar Medical.

“This divestiture allows Nordson MEDICAL to focus on its higher value growth opportunities within our $800 million medical and fluid solutions segment. This includes our growing portfolio of proprietary medical components, including balloons, cannula, nitinol devices and the recently acquired Atrion products,” said Justin Hall, executive vice president, Nordson Medical and Fluid Solutions segment. “We are confident that our contract medical design and development business will thrive under Quasar’s leadership, and we expect a smooth transition for our customers.”

Nordson MEDICAL is a global expert in the design, development and manufacturing of medical component technologies and proprietary technologies and devices. Our extensive breadth of solutions serves interventional, surgical and specialized markets with technologies that save or enhance lives. As an integrated partner, Nordson MEDICAL enables customers to save costs and speed time to market. For more information, visit www.nordsonmedical.com.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company’s direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, linkedin/Nordson, or www.facebook.com/nordson.